Batna Journal of Medical Sciences
Volume 7, Numéro 2, Pages 71-73
2020-11-09
Anticancer Drug Design: Development Of Cyclin-dependent Kinase Inhibitors Using In Silico Techniques
Authors : Matmour Derouicha .
Abstract
In mammalian cells, proliferation is controlled by the cell cycle, where cyclin-dependent kinases regulate critical checkpoints. CDK4 is considered a highly validated anticancer drug target due to its essential role in regulating cell cycle progression at the G1 restriction point. Our objective is to design novel CDK4 inhibitors using Structure-Based Drug Design and Quantitative StructureActivity Relationship techniques. We used bioinformatics tools and biological databases. QSAR study of CDK4 inhibitors has given us an idea of the physicochemical features of studied compounds and their correlation with the IC50 activity. The docking study has helped to highlight the molecule key elements to refine in order to get a more potent compound of CDK4. The Molecule under code 21366124 which has the low IC50= 3 nmole shows the most binding affinity with a score value of ΔG=-9,8 kcal/mol. As prospects, it would be very interesting to synthesize this drug candidate and to test its inhibitory activity on the cell culture of breast cancer.
Keywords
CDK4, Inhibitors, QSAR, SBDD, Docking, Breast cancer.
Les articles similaires
Sakr Ali
.
Hasegawa-johnson Mark
.
pages 63-71.
لرقط سميرة
.
قشي الخير
.
ص 341-365.
عزي صالح نعيمة
.
صادقي فاطمة
.
ص 151-169.
Kihel Ibtissem
.
Nachi Mourad
.
Entasoltan Badra
.
Bekadja Mohamed Amine
.
pages 555-560.
Tabikh S
.
Latreche S
.
Morel H
.
Maille C
.
Gontrand C
.
pages 67-72.
